DE69839273D1 - Krebs immuntherapie mit semi-allogenen zellen - Google Patents
Krebs immuntherapie mit semi-allogenen zellenInfo
- Publication number
- DE69839273D1 DE69839273D1 DE69839273T DE69839273T DE69839273D1 DE 69839273 D1 DE69839273 D1 DE 69839273D1 DE 69839273 T DE69839273 T DE 69839273T DE 69839273 T DE69839273 T DE 69839273T DE 69839273 D1 DE69839273 D1 DE 69839273D1
- Authority
- DE
- Germany
- Prior art keywords
- semi
- cells
- cancer immunotherapy
- allogeneic
- allogenic cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3662097P | 1997-01-31 | 1997-01-31 | |
US36620P | 1997-01-31 | ||
PCT/US1998/001824 WO1998033527A2 (en) | 1997-01-31 | 1998-01-30 | Cancer immunotherapy with semi-allogeneic cells |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69839273D1 true DE69839273D1 (de) | 2008-04-30 |
DE69839273T2 DE69839273T2 (de) | 2009-03-05 |
Family
ID=21889646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69839273T Expired - Lifetime DE69839273T2 (de) | 1997-01-31 | 1998-01-30 | Krebsimmuntherapie mit semi-allogenen zellen |
Country Status (7)
Country | Link |
---|---|
US (3) | US6187307B1 (de) |
EP (1) | EP1012240B1 (de) |
JP (1) | JP2001522226A (de) |
AT (1) | ATE389712T1 (de) |
CA (1) | CA2278678A1 (de) |
DE (1) | DE69839273T2 (de) |
WO (1) | WO1998033527A2 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1012240B1 (de) * | 1997-01-31 | 2008-03-19 | Edward P. Cohen | Krebs immuntherapie mit semi-allogenen zellen |
US6503503B1 (en) * | 1997-05-13 | 2003-01-07 | Duke University | Allogeneic cellular vaccine |
WO2000076537A2 (en) * | 1997-09-10 | 2000-12-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases |
EP1272224A4 (de) * | 2000-03-31 | 2004-09-29 | Gene Logic Inc | Genexpressionsprofile im gewebe der speiseröhre |
US7083787B2 (en) * | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
DE10112851C1 (de) * | 2001-03-16 | 2002-10-10 | Gsf Forschungszentrum Umwelt | Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen |
US7955845B2 (en) * | 2001-11-20 | 2011-06-07 | Dana Farber Cancer Institute, Inc. | Modified antigen-presenting cells |
WO2003103707A1 (en) * | 2002-06-06 | 2003-12-18 | Immunicum Ab | New method and composition for producing a cellular allogeneic vaccine |
US8343502B2 (en) * | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
US7439042B2 (en) * | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
ES2676503T3 (es) * | 2002-12-16 | 2018-07-20 | Globeimmune, Inc. | Vacunas basadas en levadura como inmunoterapia |
WO2004064785A2 (en) | 2003-01-14 | 2004-08-05 | Dana Farber Cancer Institute | Cancer therapy sensitizer |
US8420603B2 (en) * | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
EP2460533A3 (de) | 2004-10-18 | 2014-01-08 | Globeimmune, Inc. | Therapeutikum auf Hefebasis gegen chronische Hepatitis-C-Infection |
WO2006112930A2 (en) * | 2005-02-18 | 2006-10-26 | Abraxis Bioscience, Inc. | Q3 sparc deletion mutant and uses thereof |
CA2603191A1 (en) * | 2005-03-29 | 2006-10-05 | The Board Of Trustees Of The University Of Illinois | Cancer vaccines and therapeutic methods |
EP2268306A2 (de) * | 2008-03-14 | 2011-01-05 | The Board Of Trustees Of The University Of Illinois | Therapeutische krebsantigene |
JP2011516609A (ja) * | 2008-04-14 | 2011-05-26 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Sparc抗炎症活性及びその使用 |
JP2012503011A (ja) | 2008-09-19 | 2012-02-02 | グローブイミューン,インコーポレイテッド | 慢性c型肝炎ウイルス感染の免疫療法 |
WO2010058023A1 (en) | 2008-11-24 | 2010-05-27 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | High affinity t cell receptor and use thereof |
US9763982B2 (en) | 2010-06-29 | 2017-09-19 | The Regents Of The University Of California | Depletion of cancer stem cells |
US20120009203A1 (en) * | 2010-06-29 | 2012-01-12 | Anahid Jewett | Depletion of cancer stem cells |
JP2018090491A (ja) * | 2015-04-01 | 2018-06-14 | 株式会社細胞治療技術研究所 | 癌ワクチンの製造方法、及び癌ワクチン |
CN117838729A (zh) | 2017-04-13 | 2024-04-09 | 森迪生物科学公司 | 组合癌症免疫疗法 |
US10636512B2 (en) | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
KR20210094534A (ko) | 2018-10-17 | 2021-07-29 | 센티 바이오사이언시스, 인코포레이티드 | 병용 암 면역 요법 |
US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674486A (en) | 1991-06-25 | 1997-10-07 | San Diego Regional Cancer Center | Cancer immunotherapy with carrier cells |
JP3524918B2 (ja) | 1991-10-25 | 2004-05-10 | サン ディエゴ リージョナル キャンサー センター | 癌のリンホカイン遺伝子療法 |
IL105008A0 (en) | 1992-03-13 | 1993-07-08 | Yeda Res & Dev | Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis |
EP0569678A3 (de) | 1992-03-13 | 1994-10-26 | Yeda Res & Dev | Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen. |
US5759535A (en) * | 1994-05-13 | 1998-06-02 | Research Corporation Technologies, Inc. | Immunotherapeutic strategies for the treatment of cancer |
US6022538A (en) | 1995-06-06 | 2000-02-08 | The Wistar Institute Of Anatomy And Biology | Method of treating malignancies |
UY24367A1 (es) * | 1995-11-23 | 2000-10-31 | Boehringer Ingelheim Int | Vacunas contra tumores y procedimiento para su produccion |
US6805869B2 (en) | 1996-06-12 | 2004-10-19 | Shanghai Cp Guojian Pharmaceutical Co., Ltd. | Cellular vaccines and immunotherapeutics and methods for their preparation |
US6277368B1 (en) * | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
US6063375A (en) | 1996-09-10 | 2000-05-16 | Medical University Of South Carolina | Semiallogeneic cell hybrids and related methods for treating cancer |
GB9620350D0 (en) | 1996-09-30 | 1996-11-13 | Maudsley David J | Cancer vaccine |
EP1012240B1 (de) * | 1997-01-31 | 2008-03-19 | Edward P. Cohen | Krebs immuntherapie mit semi-allogenen zellen |
DE60128070T2 (de) | 2000-02-14 | 2008-01-10 | The Regents Of The University Of California, Oakland | Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors |
US7060802B1 (en) | 2000-09-18 | 2006-06-13 | The Trustees Of Columbia University In The City Of New York | Tumor-associated marker |
CA2603191A1 (en) | 2005-03-29 | 2006-10-05 | The Board Of Trustees Of The University Of Illinois | Cancer vaccines and therapeutic methods |
-
1998
- 1998-01-30 EP EP98904782A patent/EP1012240B1/de not_active Expired - Lifetime
- 1998-01-30 CA CA002278678A patent/CA2278678A1/en not_active Abandoned
- 1998-01-30 WO PCT/US1998/001824 patent/WO1998033527A2/en active Application Filing
- 1998-01-30 DE DE69839273T patent/DE69839273T2/de not_active Expired - Lifetime
- 1998-01-30 JP JP53311298A patent/JP2001522226A/ja active Pending
- 1998-01-30 US US09/016,528 patent/US6187307B1/en not_active Expired - Lifetime
- 1998-01-30 AT AT98904782T patent/ATE389712T1/de not_active IP Right Cessation
-
2000
- 2000-03-10 US US09/522,716 patent/US7402306B1/en not_active Expired - Fee Related
-
2008
- 2008-05-06 US US12/115,868 patent/US7670611B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7670611B2 (en) | 2010-03-02 |
US6187307B1 (en) | 2001-02-13 |
JP2001522226A (ja) | 2001-11-13 |
DE69839273T2 (de) | 2009-03-05 |
EP1012240B1 (de) | 2008-03-19 |
EP1012240A2 (de) | 2000-06-28 |
US7402306B1 (en) | 2008-07-22 |
ATE389712T1 (de) | 2008-04-15 |
US20080305131A1 (en) | 2008-12-11 |
WO1998033527A2 (en) | 1998-08-06 |
CA2278678A1 (en) | 1998-08-06 |
WO1998033527A3 (en) | 1998-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69839273D1 (de) | Krebs immuntherapie mit semi-allogenen zellen | |
Shimizu et al. | Enhancement of tumor lysate-and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein | |
Davis | An overview of cancer immunotherapy | |
EP0789574A4 (de) | Verfahren und vorrichtungen zur immunisierung eines wirts gegen tumorassoziierte antigene durch verabreichung nackter polynukleotide, die für tumorassoziierte antigene peptide kodieren | |
TR200100936T2 (tr) | Terapötik aşılama | |
Pampena et al. | Natural killer cells as helper cells in dendritic cell cancer vaccines | |
CA2267157A1 (en) | Cancer immunotherapy using tumor cells combined with mixed lymphocytes | |
ZA91559B (en) | Vaccines against cancer and infectious diseases | |
Ma et al. | Anti‐tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution | |
NO986173L (no) | FremgangsmÕte for aktivering av dendrittceller | |
Lewis | Therapeutic cancer vaccines: using unique antigens | |
CY1106400T1 (el) | Συνθεση και μεθοδος ανοσοθepαπειας με καρκινικο αντιγονο | |
Geary et al. | Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN | |
LV12085A (lv) | Dendritiskas sunas stimulejosais faktors | |
Prins et al. | Immunology and immunotherapy in neurosurgical disease | |
Assudani et al. | In vivo Expansion, Persistence, and Function of Peptide Vaccine–Induced CD8 T Cells Occur Independently of CD4 T Cells | |
ZA200401842B (en) | Process for the maturation of dentritic cells and a vaccine. | |
Wang et al. | Prime–boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice | |
WO2006062917A2 (en) | Alpha thymosin peptides as cancer vaccine adjuvants | |
Santin et al. | Effects of irradiation on the expression of surface antigens in human ovarian cancer | |
PT1171587E (pt) | Peptido derivado do antigenio muc-1 para desencadear uma reaccao imunitaria contra celulas tumorais | |
Conforti et al. | Update on active specific immunotherapy with melanoma vaccines | |
Dezfouli et al. | Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNγ primed and IFNβ treated B7‐1+ B16‐F10 melanoma cells | |
DE60130634D1 (de) | Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden | |
Sato | Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |